Erratum: Glucagon-like peptide-1 prevents methylglyoxal-induced apoptosis of beta cells through improving mitochondrial function and suppressing prolonged AMPK activation (Scientific Reports (2016) 6 (23403) DOI: 10.1038/srep23403);Glucagon-like peptide-1 prevents methylglyoxal-induced apoptosis of beta cells through improving mitochondrial function and suppressing prolonged AMPK activation

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Chang, Tien Jyun ^a   Tseng, Hsing Chi ^a,b   Liu, Meng Wei ^a   Chang, Yi Cheng ^a,b,c   Hsieh, Meng Lun ^b   Chuang, Lee Ming ^a,b  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; CYCLIC AMP DEPENDENT PROTEIN KINASE; GLUCAGON LIKE PEPTIDE 1; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; METFORMIN; METHYLGLYOXAL; PHOSPHATIDYLINOSITOL 3 KINASE;

ANIMAL; ANTAGONISTS AND INHIBITORS; APOPTOSIS; CELL SURVIVAL; DRUG EFFECTS; METABOLISM; MITOCHONDRION; PANCREAS ISLET BETA CELL; RAT; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

AMP-ACTIVATED PROTEIN KINASES; ANIMALS; APOPTOSIS; CELL LINE, TUMOR; CELL SURVIVAL; CYCLIC AMP-DEPENDENT PROTEIN KINASES; GLUCAGON-LIKE PEPTIDE 1; HYPOGLYCEMIC AGENTS; INSULIN-SECRETING CELLS; METFORMIN; MITOCHONDRIA; PHOSPHATIDYLINOSITOL 3-KINASES; PYRUVALDEHYDE; RATS; SIGNAL TRANSDUCTION;

EID: 84961590088     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep26917     Document Type: Erratum

References (50)

1. Mandrup-Poulsen, T. Beta-cell apoptosis: stimuli and signaling. Diabetes 50 Suppl 1, S58-S63 (2001).
2. Schalkwijk, C. G., Brouwers, O. & Stehouwer, C. D. Modulation of insulin action by advanced glycation end products: a new player in the field. Horm Metab Res 40, 614-619 (2008).
3. Thornalley, P. J. Endogenous alpha-oxoaldehydes and formation of protein and nucleotide advanced glycation endproducts in tissue damage. Novartis Found Symp 285, 229-243, discussion 243-246 (2007).
4. Sheader, E. A., Benson, R. S. P. & Best, L. Cytotoxic action of methylglyoxal on insulin-secreting cells. Biochem Pharmacol 61, 1381-1386 (2001).
5. Dhar, A., Dhar, I., Jiang, B., Desai, K. M. & Wu, L. Chronic methylglyoxal infusion by minipump causes pancreatic beta-cell dysfunction and induces type 2 diabetes in Sprague-Dawley rats. Diabetes 60, 899-908 (2011).
6. Hui, H., Nourparvar, A., Zhao, X. & Perfetti, R. Glucagon-like peptide-1 inhibits apoptosis of insulin-secreting cells via a cyclic 5-adenosine mono-phosphate-dependent protein kinase A and a phosphatidylinositol 3-kinase-dependent pathway. Endocrinology 144, 1444-1455 (2003).
7. Farilla, L. et al. Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats. Endocrinology 143, 4397-4408 (2002).
8. Mellado-Gil, J. M. & Aguilar-Diosdado M. High glucose potentiates cytokine and streptozotocin-induced apoptosis of rat islet cells: effect on apoptosis-related genes. J Endocrinol 183, 155-162 (2004).
9. Li, Y. et al. Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis. J Biol Chem 278, 471-478 (2003).
10. Fan, R., Li, X., Gu, X., Chan, J. C. N. & Xu, G. Exendin-4 protects pancreatic beta cells from human islet amyloid peptide-induced cell damage: potential involvement of AKT and mitochondria biogenesis. Diabetes Obes Metab 12, 815-824 (2010).
11. Tews, D. et al. Anti-apoptotic action of exandin-4 in INS-1 beta cells: comparative protein pattern analysis of isolated mitochondria. Horm Metab Res 41, 294-301 (2009).
12. Sharma, M. K., Jalewa, J. & Hölscher, C. Neuroprotective and anti-apoptotic effects of liraglutide on SH-SY5Y cells exposed to methylglyoxal stress. J Neurochem 128, 459-471 (2014).
13. Kimura, R. et al. Epidermal growth factor receptor transactivation is necessary for glucagon-like peptide-1 to protect PC12 cells from apoptosis. Neuroendocrinology 97, 300-308 (2013).
14. American Diabetes Association. Approaches to glycemic treatment. Diabetes Care 38 Suppl 1, S41-S48 (2015).
15. Zhou, G. et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 108, 1167-1174 (2001).
16. Simon-Szabó, L., Kokas, M., Mandl, J., Kéri, G. & Csala, M. Metformin attenuates palmitate-induced endoplasmic reticulum stress, serine phosphorylation of IRS-1 and apoptosis in rat insulinoma cells. PLoS One 6, e97868 (2014).
17. Masini, M. et al. Prevention by metformin of alterations induced by chronic exposure to high glucose in human islet beta cells is associated with preserved ATP/ADP ratio. Diabetes Res Clin Pract 104, 163-170 (2014).
18. Tewari M., et al. Yama/CPP32β, a mammalian homolog of CED-3, is a CrmA-inhibitable protease that cleaves the death substrate poly(ADP-ribose) polymerase. Cell 81, 801-809 (1995).
19. Hui, H., Nourparvar, A., Zhao, X. & Perfetti, R. Glucagon-like peptide-1 inhibits apoptosis of insulin-secreting cells via a cyclic 5′ -adenosine monophosphate-dependent protein kinase A- and a phosphatidylinositol 3-kinase-dependent pathway. Endocrinology 144, 1444-1455 (2003).
20. Buteau, J., et al. Glucagon-like peptide-1 prevents beta cell glucolipotoxicity. Diabetologia 47, 806-815 (2004).
21. Wang, Q., et al. Glucagon-like peptide-1 regulates proliferation and apoptosis via activation of protein kinase B in pancreatic INS-1 beta cells. Diabetologia 47, 47: 478-487 (2004).
22. Hardie, D. G., Salt, I. P., Hawley, S. A. & Davies S. P. AMP-activated protein kinase: an ultrasensitive system for monitoring cellular energy charge. Biochem J 338, 717-722 (1999).
23. Rosca, M. G., Monnier, V. M., Szweda, L. I. & Weiss, M. F. Alterations in renal mitochondrial respiration in response to the reactive oxoaldehyde methylglyoxal. Am J Physiol 283, F52-F59 (2002).
24. Shangari, N. & O'Brien, P. J. The cytotoxic mechanism of glyoxal involves oxidative stress. Biochem Pharmacol 68, 1433-1442 (2004).
25. de Arriba, S. G. et al. Methylglyoxal impairs glucose metabolism and leads to energy depletion in neuronal cells-protection by carbonyl scavengers. Neurobiol Aging 28, 1044-1050 (2007).
26. Wang, H., Liu, J. & Wu, L. Methylglyoxal-induced mitochondrial dysfunction in vascular smooth muscle cells. Biochem Pharmacol 77, 1709-1716 (2009).
27. Kennedy, E. D., Maechler, P. & Wollheim, C. B. Effects of depletion of mitochondrial DNA in metabolism secretion coupling in INS- 1 cells. Diabetes 47, 374-380 (1998).
28. Simmons, R. A., Suponitsky-Kroyter, I. & Selak, M. A. Progressive accumulation of mitochondrial DNA mutations and decline in mitochondrial function lead to beta-cell failure. J Biol Chem 280, 28785-28791 (2005).
29. 2+ and stimulates mitochondrial ATP synthesis in pancreatic MIN6 β -cells. Biochem J 369, 287-299 (2003).
30. Wu, J., Wu, J. J., Yang, L. J., Wei, L. X. & Zou, D. J. Rosiglitazone protects against palmitate-induced pancreatic beta-cell death by activation of autophagy via 5′ -AMP-activated protein kinase modulation. Endocrine 44, 87-98 (2013).
31. Meares, G. P. et al. AMP-activated protein kinase attenuates nitric oxide-induced β -cell death. J Biol Chem 285, 3191-3200 (2010).
32. Kefas, B. A. et al. AICA-riboside induces apoptosis of pancreatic beta cells through stimulation of AMP-activated protein kinase. Diabetologia 46, 250-254 (2003).
33. Cai, Y. et al. Increased oxygen radical formation and mitochondrial dysfunction mediate beta cell apoptosis under conditions of AMP-activated protein kinase stimulation. Free Radic Biol Med 42, 64-78 (2007).
34. Miao, X. Y. et al. The human glucagon-like peptide-1 analogue liraglutide regulates pancreatic beta-cell proliferation and apoptosis via an AMPK/mTOR/P70S6K signaling pathway. Peptides 39, 71-79 (2013).
35. Riboulet-Chavey, A., Diraison, F., Siew, L. K., Wong, F. S. & Rutter, G. A. Inhibition of AMP-activated protein kinase protects pancreatic β -cells from cytokine-mediated apoptosis and CD8 + T-cell-induced cytotoxicity. Diabetes 57, 415-423 (2008).
36. Kim, Y. K. et al. Protective role of glucagon-like peptide-1 against glucosamine-induced cytotoxicity in pancreatic beta cells. Cell Physiol Biochem 25, 211-220 (2010).
37. Horman, S. et al. Activation of AMP-activated protein kinase leads to the phosphorylation of elongation factor 2 and an inhibition of protein synthesis. Curr Biol 12, 1419-1423 (2002).
38. Inoki, K., Zhu, T. & Guan, K. TSC2 mediates cellular energy response to control cell growth and survival. Cell 115, 577-590 (2003).
39. Igata, M. et al. Adenosine monophosphate-activated protein kinase suppresses vascular smooth muscle cell proliferation through the inhibition of cell cycle progression. Circ Res 97, 837-844 (2005).
40. Jones, R. G. et al. AMP-activated protein kinase induces a p53-dependent metabolic checkpoint. Mol Cell 18, 283-293 (2005).
41. Kefas, B. A. et al. AMP-activated protein kinase can induce apoptosis of insulin-producing MIN6 cells through stimulation of c-Jun-N-terminal kinase. J Mol Endocrinol 30, 151-161 (2003).
42. Jambal, P. et al. Cytokine-mediated down-regulation of the transcription factor cAMP-response element-binding protein in pancreatic beta-cells. J Biol Chem 278, 23055-23065 (2003).
43. Kim, W. H. et al. AICAR potentiates ROS production induced by chronic high glucose: roles of AMPK in pancreatic beta-cell apoptosis. Cell Signal 19, 791-805 (2007).
44. Del Prato, S., Bianchi, C. & Marchetti, P. Beta-cell function and anti-diabetic pharmacotherapy. Diabetes Metab Res Rev 23, 518-527 (2007).
45. Tahrani, A. A., Bailey, C. J., Del Prato, S. & Barnett, A. H. Management of type 2 diabetes: new and future developments in treatment. Lancet 378, 182-197 (2011).
46. Moreno-Navarrete, J. M. et al. OCT1 Expression in adipocytes could contribute to increased metformin action in obese subjects. Diabetes 60, 168-176 (2011).
47. Nauck, M. et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care 32, 84-90 (2009).
48. The RISE Consortium. Restoring Insulin Secretion (RISE): design of studies of β -cell preservation in prediabetes and early type 2 diabetes across the life span. Diabetes Care 37, 780-788 (2014).
49. Ali Salim, L. Z. et al. Thymoquinone inhibits murine leukemia WEHI-3 cells in vivo and in vitro. PLoS One 9, e115340 (2014).
50. Huang, T. S., Kuo, M. L., Shew, J. Y., Chou, Y. W. & Yang, W. K. Distinct p53-mediated G1/S checkpoint responses in two NIH3T3 subclone cells following treatment with DNA-damaging agents. Oncogene 13, 625-632 (1996).